KALA BIO, Inc. (NASDAQ:KALA) CEO Sells $44,093.77 in Stock

KALA BIO, Inc. (NASDAQ:KALA) CEO Mark T. Iwicki sold 5,779 shares of the business’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $7.63, for a total transaction of $44,093.77. Following the transaction, the chief executive officer now directly owns 280,076 shares of the company’s stock, valued at approximately $2,136,979.88. This trade represents a 2.02 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

KALA BIO Stock Down 11.3 %

KALA opened at $6.82 on Friday. The stock’s 50 day moving average price is $6.70 and its 200 day moving average price is $6.33. The company has a debt-to-equity ratio of 3.18, a current ratio of 2.15 and a quick ratio of 2.15. The stock has a market cap of $31.44 million, a P/E ratio of -0.55 and a beta of -2.11. KALA BIO, Inc. has a 12 month low of $4.21 and a 12 month high of $9.25.

KALA BIO (NASDAQ:KALA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.93) EPS for the quarter, beating analysts’ consensus estimates of ($2.43) by $0.50. As a group, research analysts predict that KALA BIO, Inc. will post -10.84 earnings per share for the current year.

Hedge Funds Weigh In On KALA BIO

A hedge fund recently bought a new stake in KALA BIO stock. SR One Capital Management LP acquired a new stake in KALA BIO, Inc. (NASDAQ:KALA) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 443,661 shares of the company’s stock, valued at approximately $3,146,000. KALA BIO makes up about 1.0% of SR One Capital Management LP’s portfolio, making the stock its 9th largest position. SR One Capital Management LP owned approximately 15.76% of KALA BIO at the end of the most recent reporting period. Institutional investors own 24.61% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of KALA BIO in a research report on Friday, November 15th.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.